Willow Reviews 2026: Pricing & Verdict

Willow is not a standalone company. It is the GLP-1 weight loss brand within the Winona family, a women's telehealth platform (bywinona.com) specializing in hormone replacement therapy. Both brands share a Chief Medical Officer, Dr. Michael Green, who is dual board-certified.

The Winona connection matters for two reasons. First, it explains Willow's women-only positioning: the platform inherited Winona's patient base and clinical focus. Second, patients who use both services may benefit from coordinated care across HRT and weight management.

Willow operates at startwillow.com. It is headquartered in Austin, Texas and currently serves patients in 34 states. The company is BBB-listed but not accredited.

Willow offers compounded GLP-1 medications on a monthly subscription. Semaglutide pricing is flat. Tirzepatide pricing is tiered by dosage strength, ranging from $399 to $524 per month.

Each subscription includes provider consultations and metabolic coaching. HSA and FSA payments are accepted.

Semaglutide at $299 per month matches MEDVi and Ellie MD. Tirzepatide pricing is competitive at the $399 entry tier but climbs above competitors at higher doses. Ellie MD charges a flat $379 for tirzepatide regardless of dose. For standard dosing protocols, see our semaglutide dosage chart and tirzepatide dosage chart.

Willow is one of a growing number of telehealth platforms offering oral semaglutide tablets alongside the standard injectable format. The oral option appeals to patients who are uncomfortable with self-injection. The evidence gap, however, is significant.

The clinical trials that established semaglutide's efficacy (STEP program, 15 to 17% body weight reduction) used subcutaneous injection. Willow's oral tablets are compounded sublingual formulations, not the FDA-approved oral semaglutide (Rybelsus) made by Novo Nordisk. These compounded sublingual tablets differ in formulation, bioavailability, and absorption pathway.

No published clinical trials have evaluated compounded sublingual semaglutide for weight loss outcomes. The assumption that sublingual delivery produces equivalent results to injectable delivery has not been validated. Patients choosing the oral tablet should understand they are accepting a formulation with less clinical evidence supporting its effectiveness.

For patients who want the strongest evidence base, injectable semaglutide remains the format backed by Phase III trial data. Our semaglutide dosage calculator covers standard injectable dosing schedules.

Novo Nordisk, the manufacturer of brand-name Wegovy and Ozempic, initiated a challenge through the National Advertising Division (NAD) of BBB National Programs. NAD investigated Willow's marketing claims and found that the company used clinical data from brand-name semaglutide trials to promote compounded formulations that differ in active pharmaceutical ingredient, formulation, and administration method.

The distinction matters. Compounded semaglutide is not chemically identical to branded Wegovy. Citing Wegovy trial data (15 to 17% weight loss) to sell a compounded sublingual tablet is a claim NAD determined was not adequately supported.

Willow refused to comply with NAD's recommendations. On December 4, 2025, NAD referred the matter to state attorneys general and advertising platforms for potential enforcement action.

NAD is a self-regulatory body, not a government agency. It cannot impose fines. The referral to state AGs is the escalation mechanism used when companies refuse to cooperate. Most legitimate telehealth platforms comply with NAD proceedings. Willow's refusal is a trust signal that prospective patients should weigh carefully.

For broader regulatory context on compounded GLP-1 medications, see our FDA peptide crackdown analysis and compounded tirzepatide safety guide.

Willow holds a 3.7 out of 5 rating on Trustpilot across 313 reviews. The distribution is polarized: 56% of reviewers gave five stars; 34% gave one star. Very few reviews fall in the middle. The platform either works well for a patient or fails badly.

Positive patterns (56% five-star). Satisfied users cite genuine weight loss results, responsive coaching, and functional medication delivery. Several reviewers mention the convenience of the women-focused model and integration with Winona HRT services. The positive experiences appear legitimate and consistent.

Negative patterns (34% one-star). The complaints cluster around four categories:

1. 1.Medication delays: waiting weeks after payment before receiving shipment
2. 2.Cancellation difficulties: no self-service cancel option, unresponsive support
3. 3.Billing disputes: charges continuing after cancellation requests
4. 4.Provider access: difficulty reaching assigned clinicians, reassignments without notice

The 34% one-star rate is lower than many telehealth competitors but still represents roughly one in three patients reporting a seriously negative experience. For comparison, MEDVi holds 4.4 out of 5 on Trustpilot across 9,400+ reviews. ivim Health holds 4.0 out of 5.

Willow currently operates in 34 states. Availability depends on state telehealth regulations and pharmacy licensing requirements.

Available states: Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia, Washington, Wisconsin.

Not available: Alabama, Alaska, Arkansas, Delaware, Kansas, Louisiana, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, Utah, Vermont, West Virginia, Wyoming, and the District of Columbia.

Patients in unavailable states can consider MEDVi or Ellie MD, which serve broader geographic areas. For all sourcing options, see our where to buy peptides 2026 guide.

Willow's competitive position depends on what the patient values. The women-focused model and Winona HRT integration are unique. No other GLP-1 telehealth platform offers coordinated weight loss and hormone replacement therapy under shared medical leadership.

On pricing alone, Willow is mid-range for semaglutide and above average for tirzepatide at higher doses. ivim Health undercuts everyone on price but carries an FDA warning letter. Ellie MD offers flat tirzepatide pricing at $379 regardless of dose.

On trust signals, the NAD referral is the most significant concern. Zealthy faces a DOJ/FTC lawsuit, which is a more severe regulatory action. MEDVi has the strongest Trustpilot profile in this group at 4.4 out of 5.

Willow may be a fit if you:

• Are a woman seeking a women-focused GLP-1 platform
• Already use Winona for HRT and want coordinated care
• Live in one of the 34 available states
• Want both injectable and oral semaglutide options
• Are comfortable with the NAD referral and Trustpilot profile

Willow is not recommended if you:

• Need reliable, same-week medication delivery (delays are the top complaint)
• Want easy self-service cancellation
• Prefer a platform with a clean regulatory record (NAD referral is unresolved)
• Need tirzepatide above 7.5mg (pricing rises to $499 to $524 per month)
• Prioritize the strongest clinical evidence (oral tablet evidence is limited)

The risk-reward calculation is mixed. Willow's 56% five-star rate shows that the platform delivers for more than half its patients. The 34% one-star rate and NAD referral show that failures are neither rare nor minor. Patients who do choose Willow should document all billing interactions and confirm medication shipment timelines before each payment cycle.